These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37942289)

  • 1. Comprehensive pan-cancer investigation: unraveling the oncogenic, prognostic, and immunological significance of Abelson interactor family member 3 gene in human malignancies.
    Sun A; Cai F; Xiong Q; Xie T; Li X; Xie Y; Luo R; Hu W; Zhong F; Wang S
    Front Mol Biosci; 2023; 10():1277830. PubMed ID: 37942289
    [No Abstract]   [Full Text] [Related]  

  • 2. Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively.
    Tu Z; Ouyang Q; Long X; Wu L; Li J; Zhu X; Huang K
    Front Immunol; 2022; 13():837512. PubMed ID: 35401558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.
    Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
    Front Immunol; 2022; 13():844736. PubMed ID: 35592314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Integrated Analysis Identified TAGLN2 As an Oncogene Indicator Related to Prognosis and Immunity in Pan-Cancer.
    Pan T; Wang S; Wang Z
    J Cancer; 2023; 14(10):1809-1836. PubMed ID: 37476180
    [No Abstract]   [Full Text] [Related]  

  • 5. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive pan-cancer analysis and experiments revealed R3HDM1 as a novel predictive biomarker for prognosis and immune therapy response.
    Liu J; Bing Z; Wang J
    Front Genet; 2024; 15():1404348. PubMed ID: 39376739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cell senescence regulator p16 is a promising cancer prognostic and immune check-point inhibitor (ICI) therapy biomarker.
    Tu Z; Wang X; Cai H; Sheng Y; Wu L; Huang K; Zhu X
    Aging (Albany NY); 2023 Mar; 15(6):2136-2157. PubMed ID: 36961395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into the Oncogenic, Prognostic, and Immunological Role of BRIP1 in Pan-Cancer: A Comprehensive Data-Mining-Based Study.
    Liu Y; Wu X; Feng Y; Jiang Q; Zhang S; Wang Q; Yang A
    J Oncol; 2023; 2023():4104639. PubMed ID: 37153833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell death-related biomarker SLC2A1 has a significant role in prognosis prediction and immunotherapy efficacy evaluation in pan-cancer.
    Wang Y; Wang K; Zhang H; Jia X; Li X; Sun S; Sun D
    Front Genet; 2022; 13():1068462. PubMed ID: 36712872
    [No Abstract]   [Full Text] [Related]  

  • 12. A Comprehensive Analysis of the Prognostic, Immunological and Diagnostic Role of CCNF in Pan-cancer.
    Gao X; Bu H; Ge J; Gao X; Wang Y; Zhang Z; Wang L
    J Cancer; 2023; 14(13):2431-2442. PubMed ID: 37670965
    [No Abstract]   [Full Text] [Related]  

  • 13. Comprehensive Analysis of
    Liu J; Zhu B; Chen J; Cao Y
    Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.
    Tai P; Wang Z; Chen X; Chen A; Gong L; Cheng Y; Cao K
    Cancer Med; 2023 May; 12(10):11941-11959. PubMed ID: 36205192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer.
    Yu Y; Sun Y; Li Z; Li J; Tian D
    BMC Bioinformatics; 2023 Feb; 24(1):44. PubMed ID: 36765282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
    Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
    Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TUBB, a robust biomarker with satisfying abilities in diagnosis, prognosis, and immune regulation via a comprehensive pan-cancer analysis.
    Zhu Z; Zhang W; Huo S; Huang T; Cao X; Zhang Y
    Front Mol Biosci; 2024; 11():1365655. PubMed ID: 38756529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
    Liu P; Wang X; Pan L; Han B; He Z
    Front Immunol; 2022; 13():901784. PubMed ID: 35720327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
    Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
    J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive pan-cancer analysis on the immunological role and prognostic value of
    Yang Y; Jiang L; Wang S; Chen H; Yi M; Wu Y; Li Z; Fang X
    Transl Cancer Res; 2022 Sep; 11(9):3187-3208. PubMed ID: 36237259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.